Figure 4

48 hour exposure to 25-OHC sensitized Cox-2-negative cells to effects of Celecoxib. A/ Celecoxib concentrations of 5 and 10 μM caused the same reduction in viable cell numbers of bmLECs whether or not 25-OHC was present. Unlike bmLECs, viable numbers of bmVECs not treated with 25-OHC did not change as a result of treatment with celecoxib until the concentration was above 5 μM. Mean of fold differences between EtOH-treated (vehicle, 25-OHC untreated) bmLECs and bmVECs in the presence of 5 μM celecoxib analysed by t-test generated p-value of 0.0005 (n = 4). B/ Unlike either bmVECs or bmLECs, even 5 μM of celecoxib statistically significantly reduced viable bmAEC cell counts slightly (p = 0.012, n = 4). Cell count was reduced to a greater extent in the presence of 25-OHC. Mean fold differences between 25-OHC treated and 25-OHC untreated bmAECs at 10 μM analysed by t-test generated p-value of 0.0004 (n = 4). C/ Low doses of celecoxib also increased reduction in viable cell counts of colorectal carcinoma cells HCT-116 (previously shown to be Cox-2 deficient) in the presence of 25-OHC. Unlike ECs, viable HCT-116 cell numbers did not differ from vehicle control in the absence of 25-OHC. Mean fold difference between cell counts of HCT-116 treated and not treated with 25-OHC analysed by t-test generated p-value of 0.029 at 5 μM celecoxib, and a p-value of 0.0006 at 15 μM (n = 3).